A Web Server and Mobile App for Computing Hemolytic Potency of Peptides.

Kumardeep Chaudhary, Ritesh Kumar, Sandeep Singh, Abhishek Tuknait, Ankur Gautam, Deepika Mathur, Priya Anand, Grish C Varshney, Gajendra P S Raghava

Journal: Scientific reports 2017;6():22843

PMID: 26953092

Abstract

Numerous therapeutic peptides do not enter the clinical trials just because of their high hemolytic activity. Recently, we developed a database, Hemolytik, for maintaining experimentally validated hemolytic and non-hemolytic peptides. The present study describes a web server and mobile app developed for predicting, and screening of peptides having hemolytic potency. Firstly, we generated a dataset HemoPI-1 that contains 552 hemolytic peptides extracted from Hemolytik database and 552 random non-hemolytic peptides (from Swiss-Prot). The sequence analysis of these peptides revealed that certain residues (e.g., L, K, F, W) and motifs (e.g., "FKK", "LKL", "KKLL", "KWK", "VLK", "CYCR", "CRR", "RFC", "RRR", "LKKL") are more abundant in hemolytic peptides. Therefore, we developed models for discriminating hemolytic and non-hemolytic peptides using various machine learning techniques and achieved more than 95% accuracy. We also developed models for discriminating peptides having high and low hemolytic potential on different datasets called HemoPI-2 and HemoPI-3. In order to serve the scientific community, we developed a web server, mobile app and JAVA-based standalone software (http://crdd.osdd.net/raghava/hemopi/).

Address: Bioinformatics Centre, CSIR-Institute of Microbial Technology, Sector 39A, Chandigarh, India.; CSIR-Central Scientific Instruments Organisation, Sector 30C, Chandigarh, India.; Cell Biology and Immunology Division, CSIR-Institute of Microbial Technology, Chandigarh, India.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.